Biotech | May 27, 2022
Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
Roche and its subsidiary TIB Molbiol have developed three different LightMix Modular Virus kits for the detection of the virus
The new facility at Dombivli is the fifth ASG Eye Hospital in Maharashtra
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Subscribe To Our Newsletter & Stay Updated
